Your browser doesn't support javascript.
The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination.
Brown, Adam Harry; Shah, Sweni; Groves, Ashley M; Wan, Simon; Malhotra, Anmol.
  • Brown AH; From the Breast Unit.
  • Shah S; Department of Nuclear Medicine, Royal Free Hospital.
  • Groves AM; Institute of Nuclear Medicine, University College London, London, United Kingdom.
  • Wan S; Institute of Nuclear Medicine, University College London, London, United Kingdom.
  • Malhotra A; From the Breast Unit.
Clin Nucl Med ; 46(12): 1006-1010, 2021 Dec 01.
Article in English | MEDLINE | ID: covidwho-1165593
ABSTRACT
ABSTRACT We report a case series of biopsy-proven reactive axillary lymph nodes, which were avid on FDG PET/CT in breast cancer patients post COVID-19 vaccination. With 4 cases presenting in a consecutive 10-day period, it became apparent that metabolically active axillary lymphadenopathy is an adverse effect of COVID-19 vaccines, currently being deployed worldwide. This may lead to patients undergoing unnecessary biopsy. We have started taking a COVID-19 vaccine status history before PET/CT. If enlarged/metabolically active axillary nodes are identified in the ipsilateral vaccinated arm, then axillary ultrasound at 4 weeks is suggested.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Breast Neoplasms / COVID-19 Type of study: Prognostic study Topics: Long Covid / Vaccines Limits: Female / Humans Language: English Journal: Clin Nucl Med Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Breast Neoplasms / COVID-19 Type of study: Prognostic study Topics: Long Covid / Vaccines Limits: Female / Humans Language: English Journal: Clin Nucl Med Year: 2021 Document Type: Article